Breakthrough in cancer research: New hope for lung cancer patients!

Breakthrough in cancer research: New hope for lung cancer patients!

Laimgrubengasse 10, 1060 Wien, Österreich - The European Commission has officially issued the anti-PD 1 antibody Serplulimab, known under the brand name Hetronifly®, the approval for the treatment of advanced small cell lung cancer (ES-SCLC). This represents a groundbreaking step for patients, since Serplulimab is the first monoclonal therapy that was specially approved for first -line treatment in Europe. Developed by Henlius Biotech and in Europe via Accord Healthcare, this approval enables patients in all 27 EU member states as well as in Norway, Iceland and Liechtenstein, an urgently needed new therapy option. According to the Accord Executive Paul Tredwell, this admission shows that the company has undertaken to improve patients and offer innovative treatments that may allow more time with their relatives, as in the report of Krebs-Nachrichten is highlighted.

Serplulimab is a new weapon in the fight against small cell lung cancer, which only makes up 15 to 20 % of all lung cancer cases, but is known for its aggressive nature and poor forecast. This means that Serplulimab is part of decisive growth in the oncology market and offers hope for patients who have had only limited treatment options. This development could make a significant contribution to further consolidating the treatment spectrum for lung cancer patients in Europe and at the same time to further consolidate Accord's commitment to alleviating global challenges in the field of cancer. It remains to be seen how this new therapy will prove itself in clinical practice and what further steps are taken by the partner companies in order to optimize the availability of Serplulimab.